Miederer S E, Lindstaedt H, Kutz K, Wuttke H
Dtsch Med Wochenschr. 1979 Mar 2;104(9):313-5. doi: 10.1055/s-0028-1103902.
In a double-blind trial 16 persons with gastric ulcer and 35 with duodenal ulcer were treated as out-patients with 1200 mg proglumide daily or 1320 mg magnesium tricilicate daily (as an "active placebo") for four weeks. The ulcers were assessed by endoscopy before and after treatment. The gastric ulcers disappeared in 75% of patients receiving proglumide (six of eight subjects) but in only 25% of those on the placebo (two of eight). There was no significant effect of proglumide on duodenal ulcers (17 in the proglumide and 18 in the placebo groups). Proglumide failed to affect either basal or maximally stimulated acid secretion, nor was there any change in the serum gastrin level. There were no side effects during proglumide administration. This underlines its therapeutic value in the treatment of gastric ulcer, in comparison with cimetidine or carbenoxolone.
在一项双盲试验中，16名胃溃疡患者和35名十二指肠溃疡患者作为门诊病人接受治疗，每天服用1200毫克丙谷胺或每天服用1320毫克三硅酸镁（作为“活性安慰剂”），为期四周。在治疗前后通过内窥镜检查对溃疡进行评估。接受丙谷胺治疗的患者中75%（8名受试者中的6名）的胃溃疡消失，但服用安慰剂的患者中只有25%（8名中的2名）的胃溃疡消失。丙谷胺对十二指肠溃疡没有显著影响（丙谷胺组17例，安慰剂组18例）。丙谷胺未能影响基础胃酸分泌或最大刺激胃酸分泌，血清胃泌素水平也没有任何变化。服用丙谷胺期间没有副作用。与西咪替丁或甘珀酸相比，这突出了其在治疗胃溃疡方面的治疗价值。
